SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

31 Oct 2025 Evaluate
The company witnessed a 9.44% growth in the revenue at Rs. 52257.20 millions for the quarter ended September 2025 as compared to Rs. 47750.30 millions during the year-ago period.Net profit showed a marginal rise at Rs. 12105.30 millions for the quarter ended September 2025, as compared to corresponding quarter of last year.OP of the company witnessed a marginal growth to 17772.90 millions from 17271.80 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 52257.20 47750.30 9.44 102718.90 92760.80 10.74 190448.50 165743.40 14.91
Other Income 2546.60 2891.40 -11.93 5257.30 5026.60 4.59 9847.20 10706.60 -8.03
PBIDT 17772.90 17271.80 2.90 36728.10 33005.60 11.28 67631.60 55548.10 21.75
Interest 26.50 30.00 -11.67 85.30 80.70 5.70 151.10 202.50 -25.38
PBDT 17746.40 17241.80 2.93 36642.80 32924.90 11.29 70427.10 55345.60 27.25
Depreciation 1413.00 1457.10 -3.03 2869.90 2835.70 1.21 5738.90 5875.90 -2.33
PBT 16333.40 15784.70 3.48 33772.90 30089.20 12.24 64688.20 49469.70 30.76
TAX 4228.10 4003.10 5.62 8636.30 7748.20 11.46 13111.70 12327.80 6.36
Deferred Tax 105.90 -64.20 -264.95 -46.30 101.70 -145.53 -491.50 60.90 -907.06
PAT 12105.30 11781.60 2.75 25136.60 22341.00 12.51 51576.50 37141.90 38.86
Equity 1615.50 1615.10 0.02 1615.50 1615.10 0.02 1615.20 1614.70 0.03
PBIDTM(%) 34.01 36.17 -5.97 35.76 35.58 0.49 35.51 33.51 5.96

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×